Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis.
Hernandez L, Guo S, Toro-Diaz H, Carroll S, Syed Farooq S F
J Med Econ. 2016 Oct 12:1-29. PMID: 27730845.Abstract
